I own shares of both companies. In my view Medafor management is doing just fine. They have grown sales at 60% a year for the past 3 years. The next 3 years look great too. On the other hand, what was CRY's sales growth rate over this period...perhaps 10% a year...? Think about what this metric does over time. Now ask yourself which company is better managed.
Private companies have no symbol. Shareholders of private companies get the information that they are entitled to by law. This includes periodic financial information. CRY is a public company. Much of their information is available online. I take information from both sources, apply a little math, and try to figure things out.
I have no problem selling my shares to CRY, assuming the price and terms would be satisfactory. In my view though, I think Medafor shares are worth considerably more than more than $2/share.
Let me give you an example. Assume Medafor shares today are fairly valued at $3/share. Medafor revenues have been growing about 60%/year for the past 3 years. It looks like this growth can continue for the next 3 years as well. This means that if Medafor operates its business model the stock would double in value every 18-20 months. This is because revenues would double every 18-20 months, as would net income, as would stock value. That means $3/share today becomes $6/share in 18-20 months, and $12/share in roughly 36-40 months. That is simply put, but that is pretty much the story too.
I think something else is the case too. If CRY were to acquire Medafor, the combined company would have a much faster rate of revenue growth. Because of the high HemoStase gross/net margins, the combined company revenue multiplier would probably double overnight. This would likely result in the new CRY stock probably doubling over a short period of time.